Global Diagnostic Radiopharmaceuticals & Contrast Media Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In October 2022, Duchem Bio introduced FACBC, the first radiopharmaceutical in the world specifically for diagnosing prostate cancer patients, to the Korean market. FACBC had previously been approved in the United States in 2016 and the European Union in 2017. Since then, it has been used with around 196,000 patients.

• In January 2021, QSAM Biosciences Inc. reported promising outcomes from a study assessing radioactive impurity levels in its leading drug candidate, Samarium-153-DOTMP (also known as CycloSam). The study results suggest a positive safety profile for CycloSam and indicate potential broader applications if the drug is eventually approved for commercial use.

This report extensively covers different segments of Global Diagnostic Radiopharmaceuticals & Contrast Media Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments. In this report, the analysis for every market segment is substantiated with relevant data points and, insights that are generated from analysis of these data points (data trends and patterns).

The market is segmented into different categories based on product type and geography. These segments help in understanding market dynamics and trends in various regions and product categories.

In the radiopharmaceuticals segment, the market is divided into different types of radiotracers used for nuclear medicine imaging procedures such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). The contrast media segment encompasses various types of contrast agents used in medical imaging procedures such as X-ray, computed tomography (CT), and magnetic resonance imaging (MRI).

Geographically, the market is segmented into five key regions: North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. Each region exhibits unique market trends and growth opportunities based on factors such as healthcare infrastructure, adoption of advanced medical imaging technologies, and regulatory environments.

Global Diagnostic Radiopharmaceuticals & Contrast Media Segment Analysis

In this report, the Global Diagnostic Radiopharmaceuticals & Contrast Media Market has been segmented by Radiopharmaceuticals, Contrast Media, and Geography.

Global Diagnostic Radiopharmaceuticals & Contrast Media Market, Segmentation by Radiopharmaceuticals

The Global Diagnostic Radiopharmaceuticals & Contrast Media Market has been segmented by Radiopharmaceuticals into By Type of Imaging Modality (SPECT and PET), and By Application (Diagnostic application and Therapeutic application).

By type of imaging modality, SPECT and PET imaging play critical roles in nuclear medicine by providing high-quality diagnostic imaging for various medical conditions. SPECT is a well-established modality that uses radiotracers to create detailed images of how organs and tissues function. It is widely used for cardiac and brain imaging and can also provide valuable insights into other conditions such as cancer and bone disorders. PET, on the other hand, is known for its advanced imaging capabilities, providing metabolic and physiological information. It is particularly useful in oncology for detecting and staging cancer, as well as monitoring response to therapy.

By application, radiopharmaceuticals can be used for both diagnostic and therapeutic purposes. Diagnostic applications include using radiotracers to visualize and assess organ function, tissue metabolism, and blood flow. These applications are vital for diagnosing a range of diseases, including cardiovascular disease, neurological disorders, and cancer. Therapeutic applications involve the use of radiopharmaceuticals to treat certain conditions, particularly in oncology. For instance, targeted radionuclide therapy is an emerging treatment option for specific types of cancer, such as prostate and thyroid cancers.

Global Diagnostic Radiopharmaceuticals & Contrast Media Market, Segmentation by Contrast Media

The Global Diagnostic Radiopharmaceuticals & Contrast Media Market has been segmented by Contrast Media into By Procedure (X-Ray/Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasound), and By Application (Cardiovascular Disease, Oncology, Gastrointestinal Disorders, Neurological Disorders, and Others).

When considering the market by procedure, the use of contrast media in X-ray/CT scans is one of the most common applications. In X-ray/CT scans, iodine-based and barium-based contrast agents are typically used to improve the visibility of blood vessels, gastrointestinal tract, and other anatomical structures. This enhancement allows radiologists to identify abnormalities and diagnose conditions such as blockages, tumors, and internal bleeding more effectively.

In the case of MRI, gadolinium-based contrast agents are predominantly used to enhance images. MRI provides high-resolution images of soft tissues, and the addition of contrast agents helps improve the differentiation of normal and abnormal tissues. This is particularly useful in assessing neurological conditions, musculoskeletal disorders, and tumors in various parts of the body.

For ultrasound procedures, contrast-enhanced ultrasound (CEUS) uses microbubble contrast agents that improve the clarity and detail of ultrasound images. CEUS is beneficial for assessing blood flow and perfusion in organs such as the liver, kidneys, and heart. It can be particularly useful in oncology for evaluating tumor vascularization and in cardiology for assessing cardiac function.

In terms of application, contrast media plays a critical role in diagnosing and monitoring cardiovascular diseases. Contrast-enhanced imaging allows physicians to visualize blood vessels, assess blood flow, and identify blockages, which is essential for the diagnosis and management of conditions such as coronary artery disease and peripheral vascular disease.

Contrast media is also widely used in oncology for detecting tumors and assessing their size, location, and spread. Enhanced imaging techniques provide crucial information for staging cancer, planning treatment, and monitoring response to therapy. Additionally, contrast media is used in gastrointestinal disorders to visualize the structure and function of the digestive system, helping in the diagnosis of conditions such as inflammatory bowel disease and gastrointestinal bleeding. In neurological disorders, contrast agents enhance the visualization of brain and spinal cord structures, aiding in the diagnosis of conditions such as multiple sclerosis and brain tumors.

Global Diagnostic Radiopharmaceuticals & Contrast Media Market, Segmentation by Geography

In this report, the Global Diagnostic Radiopharmaceuticals & Contrast Media Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Diagnostic Radiopharmaceuticals & Contrast Media Market Share (%), by Geographical Region, 2024

North America is a leading market for diagnostic radiopharmaceuticals and contrast media, due to its well-established healthcare infrastructure, high healthcare expenditure, advanced medical imaging technologies, and a large base of patients with chronic diseases. The region's emphasis on research and development and the presence of key market players further contribute to its dominance.

Europe is another significant market, with a strong focus on healthcare innovation and a high adoption rate of advanced medical imaging technologies. The region also has a well-structured healthcare system, which supports the growth of the market.

The Asia Pacific region is expected to experience substantial growth due to the increasing prevalence of chronic diseases, rising healthcare expenditure, and the growing adoption of advanced medical imaging techniques. Additionally, the expanding healthcare infrastructure and increasing awareness of early diagnosis and treatment options contribute to the market's growth in the region.

The Middle East and Africa region is gradually witnessing an increase in demand for diagnostic radiopharmaceuticals and contrast media due to the improvement of healthcare infrastructure and the rising incidence of chronic diseases. Challenges such as limited access to advanced healthcare services and economic constraints may hinder rapid market growth.

Latin America is another emerging market for diagnostic radiopharmaceuticals and contrast media, driven by the growing prevalence of chronic diseases, increasing healthcare expenditure, and rising demand for advanced medical imaging techniques.

This report provides an in depth analysis of various factors that impact the dynamics of Global Diagnostic Radiopharmaceuticals & Contrast Media Market. These factors include; Market Drivers, Restraints, and Opportunities Analysis.

Drivers, Restraints, and Opportunities Analysis

Drivers:

• Advancements in Imaging Technologies
• Growing Prevalence of Chronic Diseases
• Increasing Geriatric Population
• Favorable Regulatory Approvals

• Awareness of Early Diagnosis - Awareness of early diagnosis plays a critical role in driving the global diagnostic radiopharmaceuticals and contrast media market. As medical knowledge and public health education have improved worldwide, more individuals understand the importance of detecting diseases in their initial stages. Early diagnosis allows for more effective treatment and management of conditions such as cancer, cardiovascular diseases, and neurological disorders.

  Healthcare providers are increasingly emphasizing screening programs and diagnostic imaging to detect these diseases before they progress. Patients and their families are also becoming more proactive in seeking early diagnosis to improve health outcomes and quality of life. This shift in mindset is leading to greater demand for radiopharmaceuticals and contrast media, which are essential components of advanced diagnostic procedures.

  Early diagnosis not only improves the chances of successful treatment but also helps in reducing healthcare costs by preventing the progression of diseases to more advanced stages. As a result, governments and healthcare organizations are supporting initiatives to promote early diagnosis through awareness campaigns and preventive healthcare measures.

Restraints:

• Potential Side Effects and Risks
• Lack of Skilled Professionals
• Reimbursement Challenges

• Short Half-Life of Isotopes - The short half-life of isotopes presents a significant restraint in the global diagnostic radiopharmaceuticals and contrast media market. Radiopharmaceuticals utilize radioactive isotopes to create images for diagnosing various diseases, such as cancer and cardiovascular conditions. The inherent nature of isotopes means they undergo radioactive decay relatively quickly, resulting in a short shelf life.

  Due to the short half-life of isotopes, radiopharmaceuticals need to be manufactured and transported quickly to healthcare facilities. This poses logistical challenges as they must be used within a limited timeframe, leading to potential supply chain issues. Healthcare providers must carefully manage inventory to ensure they have enough radiopharmaceuticals available for scheduled procedures while minimizing waste due to the isotopes' decay.

  The short half-life of isotopes also affects the availability of radiopharmaceuticals in regions where advanced manufacturing facilities are limited. Hospitals and clinics in such areas may face delays in obtaining the necessary isotopes for diagnostic procedures, which could hinder patient care and treatment planning. The short half-life of isotopes requires a highly efficient and well-coordinated production and distribution network. This can increase the operational costs for manufacturers and suppliers, ultimately impacting the overall affordability and accessibility of radiopharmaceuticals.

Opportunities:

• Emergence of Novel Radiopharmaceuticals
• Adoption of Artificial Intelligence
• Growth in Nuclear Medicine

• Focus on Personalized Medicine - The growing focus on personalized medicine presents a significant opportunity in the global diagnostic radiopharmaceuticals and contrast media market. Personalized medicine aims to tailor medical treatments and diagnostic approaches to individual patients based on their unique genetic makeup, medical history, and specific health conditions. This approach is transforming the way diseases are diagnosed and treated, and it holds great potential for the diagnostic radiopharmaceuticals and contrast media market.

  In the context of diagnostic radiopharmaceuticals and contrast media, personalized medicine involves using these agents to obtain highly detailed and accurate imaging that can provide insights into an individual's specific health condition. This level of precision allows for more targeted and effective diagnostic procedures, enabling healthcare providers to better understand the disease's progression and make informed decisions regarding treatment options.

  As personalized medicine becomes more prevalent, there is a growing demand for advanced diagnostic radiopharmaceuticals and contrast media that can be tailored to individual patient needs. This demand drives research and development in the market, leading to the creation of innovative products with improved efficacy and safety profiles.

Key players in Global Diagnostic Radiopharmaceuticals & Contrast Media Market include,

• NTP Radioisotopes SOC Ltd
• Bayer AG
• Bracco Imaging SpA
• Curium Pharma
• GE Company (GE Healthcare)
• Guerbet Group
• Lantheus Holdings Inc.
• Cardinal Health Inc.
• Nano Therapeutics Pvt Ltd
• Siemens Healthineers
• Trivitron Healthcare
• Koninklijke Philips NV
• Triad Isotopes
• Spago Nanomedical AB
• Otsuka Pharmaceuticals Co. Ltd

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis